You are a helpful, respectful, and honest assistant. Always answer as helpfully as possible, while being safe. Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content. Please ensure that your responses are socially unbiased and positive in nature. If a question does not make any sense or is not factually coherent, explain why instead of answering something not correct. If you don't know the answer to a question, please don't share false information.
What is A 52 year-old postmenopausal patient has evidence of low bone mineral density. She and her physician are considering therapy with raloxifene or a combination of conjugated estrogens and medroxyprogesterone acetate. Which of the following patient characteristics is MOST likely to lead them to select raloxifene? and explain in detail?
-Raloxifene is a SERM used in post-menopausal osteoporosis due to its agonist action in bone. -It has additional advantage of causing decrease in risk of breast and endometrial cancer due to its estrogen antagonists action at these places. -Major adverse effect of raloxifene is thromboembolism and aggravation of hot flushes of menopause.